Thermo Fisher Scientific Inc.
TMOFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
42,879
Cost of Revenue
25,151
Gross Profit
17,728
Gross Margin
41.3%
Operating Income
7,662
Operating Margin
17.9%
Net Income
6,335
Net Margin
14.8%
EPS (Basic)
$16.58
EPS (Diluted)
$16.53
EBITDA
11,800
EBITDA Margin
27.5%
2023
12/31/2023
Revenue
42,857
Cost of Revenue
25,663
Gross Profit
17,194
Gross Margin
40.1%
Operating Income
7,446
Operating Margin
17.4%
Net Income
5,995
Net Margin
14.0%
EPS (Basic)
$15.53
EPS (Diluted)
$15.45
EBITDA
11,195
EBITDA Margin
26.1%
2022
12/31/2022
Revenue
44,915
Cost of Revenue
25,904
Gross Profit
19,011
Gross Margin
42.3%
Operating Income
8,525
Operating Margin
19.0%
Net Income
6,950
Net Margin
15.5%
EPS (Basic)
$17.73
EPS (Diluted)
$17.64
EBITDA
11,942
EBITDA Margin
26.6%
2021
12/31/2021
Revenue
39,211
Cost of Revenue
19,577
Gross Profit
19,634
Gross Margin
50.1%
Operating Income
10,318
Operating Margin
26.3%
Net Income
7,725
Net Margin
19.7%
EPS (Basic)
$19.61
EPS (Diluted)
$19.46
EBITDA
11,969
EBITDA Margin
30.5%
2020
12/31/2020
Revenue
32,218
Cost of Revenue
16,191
Gross Profit
16,027
Gross Margin
49.7%
Operating Income
7,897
Operating Margin
24.5%
Net Income
6,375
Net Margin
19.8%
EPS (Basic)
$16.10
EPS (Diluted)
$15.98
EBITDA
10,108
EBITDA Margin
31.4%